WALLACE PURDY: Open Payments
NPI 1528166832 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$745 in 40 payments from 9 companies in 2025. Trend: 2023 $332 · 2024 $313 · 2025 $745
Food & beverage: $745
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $229 |
| Novo Nordisk Inc | 5 | $110 |
| Amgen Inc. | 6 | $98 |
| Esperion Therapeutics, Inc. | 6 | $94 |
| ABBVIE INC. | 3 | $68 |
| Lilly USA, LLC | 3 | $51 |
| PFIZER INC. | 2 | $51 |
| Aroa Biosurgery Incorporated | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: FARXIGA, REPATHA, NEXLETOL, Ozempic, AIRSUPRA, MOUNJARO, ELIQUIS, UBRELVY.
Industry payments across AL — which companies pay providers there.
